REGENXBIO Inc. (NASDAQ: RGNX) recently saw transaction activity from its executive leadership as Chief Medical Officer Steve Pakola sold 15,309 shares of common stock on May 11, 2026. The total value of the sale amounted to $168,705, with execution occurring at a weighted average price of $11.02 per share. These sales were executed within a range of $11.00 to $11.10 per share under a Rule 10b5-1 trading plan.
Key Transaction and Clinical Details
The sale by Mr. Pakola follows a series of notable developments for the gene therapy developer. On the financial front, REGENXBIO reported its fourth-quarter results, which included revenue of $30.3 million and a net loss of $61.7 million, or $1.30 per share. For the full fiscal year, the company recorded total revenue of $170.4 million alongside a net loss of $193.9 million, representing a loss of $3.76 per share.
In terms of legal and regulatory matters, REGENXBIO entered into a $10 million settlement with GlaxoSmithKline regarding allegations of underpaid sublicense fees. The company is scheduled to fulfill this $10 million payment within three business days following the effective date of the settlement.
Clinically, the company has reported positive interim data from its Phase I/II AFFINITY DUCHENNE trial for RGX-202. The data indicated improved performance in study participants when compared to external controls. This clinical progress has drawn attention from several investment firms:
- Stifel: Reiterated a Buy rating with a price target of $42, noting the potential for RGX-202 to serve as a best-in-class treatment.
- Clear Street: Maintained a Buy rating and set a $45 price target, suggesting the market has undervalued the company's early gene therapy data.
- H.C. Wainwright: Kept a Buy rating but adjusted its price target from $32 down to $30.
Market Impact and Sector Analysis
Key Points:
- Executive Liquidity: The sale of shares by the Chief Medical Officer via a 10b5-1 plan provides insight into executive portfolio management during active clinical trial phases. This impacts the biotech sector by highlighting how leadership manages equity amid volatility.
- Clinical Catalysts: The positive interim data from the RGX-202 trial in the AFFINITY DUCHENNE study serves as a significant driver for the gene therapy market, influencing valuation models and analyst sentiment.
- Institutional Outlook: Divergent price targets from Stifel, Clear Street, and H.C. Wainwright reflect varying valuation expectations within the healthcare investment community.
Risks and Uncertainties:
- Financial Volatility: The company's reported net losses (including a $193.9 million full-year loss) and the 29% year-to-date decline in stock price highlight the inherent financial risks in the high-growth biotech sector.
- Legal Liabilities: The $10 million settlement with GlaxoSmithKline regarding sublicense fees illustrates the regulatory and contractual risks that can impact corporate cash flows.
- Valuation Discrepancies: There is a notable gap between current trading prices ($10.04) and various analyst price targets (ranging from $30 to $45), representing uncertainty in market timing and asset valuation.